Search

Author/Creator Arteaga, C L

1. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. (27th August 2019)

Authors:
Jhaveri, K L; Wang, X V; Makker, V; Luoh, S -W; Mitchell, E P; Zwiebel, J A; Sharon, E; Gray, R J; Li, S; McShane, L M; Rubinstein, L V; Patton, D; Williams, P M; Hamilton, S R; Conley, B A; Arteaga, C L; Harris, L N; O'Dwyer, P J; Chen, A P; Flaherty, K T
Journal:
Annals of oncology
Issue:
Volume 30:Number 11(2019)
Page Start:
1821
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (13th August 2019)

Authors:
Hortobagyi, G N; Stemmer, S M; Burris, H A; Yap, Y S; Sonke, G S; Paluch-Shimon, S; Campone, M; Petrakova, K; Blackwell, K L; Winer, E P; Janni, W; Verma, S; Conte, P; Arteaga, C L; Cameron, D A; Mondal, S; Su, F; Miller, M; Elmeliegy, M; Germa, C
Journal:
Annals of oncology
Issue:
Volume 30:Number 11(2019)
Page Start:
1842
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (27th April 2018)

Authors:
Hortobagyi, G N; Stemmer, S M; Burris, H A; Yap, Y S; Sonke, G S; Paluch-Shimon, S; Campone, M; Petrakova, K; Blackwell, K L; Winer, E P; Janni, W; Verma, S; Conte, P; Arteaga, C L; Cameron, D A; Mondal, S; Su, F; Miller, M; Elmeliegy, M; Germa, C
Journal:
Annals of oncology
Issue:
Volume 29:Number 7(2018)
Page Start:
1541
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search